News

Growth stocks are back in style after getting battered in last year's downturn. Some, though, never went out of fashion in the first place. That's the case with this trio of biotech stocks: Vertex

Despite what many people think, the pandemic isn't officially over yet. And while the world has made tremendous progress, the coronavirus continues to cause problems. COVID-19 cases and

"I don't get no respect." That was the line the late comedian Rodney Dangerfield made famous. But it could also apply to some stocks.

Three Motley Fool contributors identified surprisingly

Shares of Premier (NASDAQ: PINC) are down 15.5% this week as of 12:05 p.m. ET Friday, according to data provided by S&P Global Market Intelligence, after the healthcare-improvement leader announced

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea

Companies that can withstand market volatility make for good long-term investments. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, has repeatedly demonstrated

Analysts' price targets can help investors get an idea of whether there's a lot of bullishness surrounding a stock. But in some cases, a high upside can simply be due to elevated price targets that

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

Shares of Medtronic (NYSE: MDT) fell 3.1% on Thursday, according to data provided by S&P Global Market Intelligence, giving back yesterday's post-earnings gains after it announced advisors to the

Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in

Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in

Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic

Novo Nordisk's (NYSE: NVO) molecule semaglutide is the active ingredient in its smash-hit therapies for weight loss and diabetes, which you've probably heard of under the trade names Wegovy and

News from the Food and Drug Administration (FDA) can often make or break a stock. This month, it broke Sage Therapeutics (NASDAQ: SAGE).

Although the company obtained approval for its depression

Growth stocks have hit a rough patch lately. The Nasdaq Composite, a benchmark for many growth-oriented companies, has declined by about 5% since the beginning of August, and many individual growth

If Wall Street is having a back-to-school sale, Cathie Wood is shopping. The widely followed growth investor who leads Ark Invest did a fair amount of buying on Tuesday. She publishes her daily

More than three years after deeming COVID-19 a global health emergency, the World Health Organization ended the pandemic's special status in May.

This was certainly welcome news for numerous

Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as

By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a